Canton Strategic Holdings, Inc.

Canton Strategic Holdings, Inc. is a publicly traded company focused on leveraging Canton Coin to support the Canton Network, the first privacy-enabled public blockchain processing $9 trillion in monthly transaction volume. Formerly Tharimmune, Inc., it rebranded effective February 18, 2026, aligning with its digital asset treasury strategy initiated through a $545 million private placement in November 2025. The company drives value via Canton Coin acquisition, operation of a Super Validator on the network, and investments in applications that promote institutional utility and adoption across capital markets. It remains the first and only publicly traded entity backed by the Canton Foundation, featuring institutional expertise on its board, including former CFTC Commissioner Jill Sommers. Additionally, Canton Strategic Holdings maintains clinical-stage biotech research and development in inflammation and immunology. Key milestones include a $55 million registered offering for expansion and quarterly ecosystem reporting commitments. Positioned at the forefront of digitizing traditional financial markets, it facilitates onchain innovations like tokenized U.S. Treasury securities and enterprise payroll solutions.

Sector

Healthcare

Industry

Biotechnology

CEO

Mr. Mark Wendland

Employees

12

Headquarters

Red Bank, NJ, United States

Website

www.cantonstrategic.com